Expanded Access for CC-486
NCT03723135 · Status: APPROVED_FOR_MARKETING · Type: EXPANDED_ACCESS
Last updated 2020-09-18
Summary
This is an expanded access program (EAP) for eligible participants designed to provide access to CC-486.
Conditions
- Acute Myelogenous Leukemia (AML)
Interventions
- DRUG
-
CC-486
Oral azacitidine administered as directed by treating physician.
Sponsors & Collaborators
-
Celgene
lead INDUSTRY
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
Countries
- United States
Study Locations
More Related Trials
-
Nilotinib, for Patients With CML-CP or CML-AP
NCT04518644 ·Status: NO_LONGER_AVAILABLE
-
AG-858 in Patients Who Are Cytogenetically Positive After Treatment With Gleevec™
NCT00058747 ·Status: TERMINATED ·Phase: PHASE2
-
Study to Determine the Optimal Biologic Dose of CC-401 in Subjects With High-Risk Myeloid Leukemia
NCT00126893 ·Status: TERMINATED ·Phase: PHASE1
-
Oral Azacitidine (CC-486) Epigenetic Priming and Maintenance for Adult Acute Myeloid Leukemia (AML) Patients
NCT06180863 ·Status: WITHDRAWN ·Phase: PHASE2
-
Study of Vaccination With Autologous Acute Myeloblastic Leukemia Cells in Patients With Advanced Myelodysplasia or Acute Myelogenous Leukemia
NCT00136422 ·Status: COMPLETED ·Phase: PHASE1
-
Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): DNA Microarray Gene Expression Analysis
NCT00001586 ·Status: COMPLETED ·Phase: PHASE2
-
CPX-351 as a Novel Approach for the Treatment of Older Patients With AML and MDS
NCT04668885 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
CC-486 and Venetoclax for Acute Myeloid Leukemia
NCT05287568 ·Status: RECRUITING ·Phase: PHASE1
-
Risk-Group Classification of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
NCT00482352 ·Status: COMPLETED
-
Phase 2 Study Assessing the Clinical Activity and Safety of Obecabtagene Autoleucel as a Consolidation in Patients With Newly Diagnosed High-risk B-cell Acute Lymphocytic Leukemia (ALL)
NCT07053059 ·Status: RECRUITING ·Phase: PHASE2
-
Expanded Access to Ziftomenib
NCT05738538 ·Status: AVAILABLE
-
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
NCT06137118 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Safety Study of AP24534 to Treat Chronic Myelogenous Leukemia (CML) and Other Hematological Malignancies
NCT00660920 ·Status: COMPLETED ·Phase: PHASE1
-
Diagnostic Study of Patients With Acute Lymphoblastic Leukemia or Acute Promyelocytic Leukemia
NCT00003861 ·Status: ACTIVE_NOT_RECRUITING
-
Study of CC-96191 in Participants With Relapsed or Refractory Acute Myeloid Leukemia
NCT04789655 ·Status: TERMINATED ·Phase: PHASE1
-
Study of LY573636-sodium in Essential Thrombocythemia and Acute Myeloid Leukemia
NCT00718159 ·Status: COMPLETED ·Phase: PHASE1
-
FT538 in Subjects With Advanced Hematologic Malignancies
NCT04614636 ·Status: TERMINATED ·Phase: PHASE1
-
A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological Disorders
NCT02494258 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate MK-0482 for Relapsed/Refractory Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML) (MK-0482-002)
NCT05038800 ·Status: TERMINATED ·Phase: PHASE1
-
Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia
NCT00046683 ·Status: COMPLETED ·Phase: PHASE3
-
Expanded Access Program for OOS Obe-cel
NCT06799221 ·Status: AVAILABLE
-
Safety and Efficacy Study of CC-486 in Subjects With Myelodysplastic Syndromes
NCT02281084 ·Status: COMPLETED ·Phase: PHASE2
-
A Safety Study of SGN-CD123A in Patients With Acute Myeloid Leukemia
NCT02848248 ·Status: TERMINATED ·Phase: PHASE1
-
Lintuzumab-Ac225 in Combination with Cladribine + Cytarabine + Filgastrim + Mitoxantrone (CLAG-M) for Relapsed/Refractory Acute Myeloid Leukemia
NCT03441048 ·Status: COMPLETED ·Phase: PHASE1
-
Advanced Chronic Myelogenous Leukemia (CML) - Follow On: Study of BMS-354825 in Subjects With CML
NCT00123487 ·Status: COMPLETED ·Phase: PHASE3